TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Corvus Pharmaceuticals ( (CRVS) ) just unveiled an announcement.
On October 2, 2025, Corvus Pharmaceuticals appointed David Moore as a Class III director to its Board, with his term set to expire in 2028. Mr. Moore will also serve on the Compensation and Nominating Committees, receiving compensation through an annual retainer, stock options, and additional cash for his committee roles, aligning with the company’s non-employee director compensation program.
The most recent analyst rating on (CRVS) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Corvus Pharmaceuticals stock, see the CRVS Stock Forecast page.
Spark’s Take on CRVS Stock
According to Spark, TipRanks’ AI Analyst, CRVS is a Neutral.
Corvus Pharmaceuticals exhibits significant financial difficulties with no revenue and increasing losses. Technical indicators show a bearish trend, and valuation metrics are weak. However, clinical advancements and strategic governance changes provide some optimism. Overall, the stock is rated at the lower end of the scale due to its financial challenges and negative technical trends, with potential upside from clinical developments.
To see Spark’s full report on CRVS stock, click here.
More about Corvus Pharmaceuticals
Corvus Pharmaceuticals is a company operating in the pharmaceutical industry, focusing on developing innovative therapies for cancer and immune disorders.
Average Trading Volume: 571,967
Technical Sentiment Signal: Strong Buy
Current Market Cap: $541M
Find detailed analytics on CRVS stock on TipRanks’ Stock Analysis page.